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Key points
• Bile acids, ethanol and fatty acids affect pancreatic ductal fluid and bicarbonate secretion via
mitochondrial damage, ATP depletion and calcium overload.
• Pancreatitis-inducing factors open the membrane transition pore (mPTP) channel via cyclo-
philin D activation in acinar cells, causing calcium overload and cell death; genetic or
pharmacological inhibition of mPTP improves the outcome of acute pancreatitis in animal
models.
• Here we show that genetic and pharmacological inhibition of mPTP protects mitochondrial
homeostasis and cell function evoked by pancreatitis-inducing factors in pancreatic ductal
cells.
• The results also show that the novel cyclosporin A derivative NIM811 protects mitochondrial
function in acinar and ductal cells, and it preserves bicarbonate transport mechanisms in
pancreatic ductal cells.
• We found that NIM811 is highly effective in different experimental pancreatitis models and
has no side-effects. NIM811 is a highly suitable compound to be tested in clinical trials.
Abstract Mitochondrial dysfunction plays a crucial role in the development of acute pancreatitis
(AP); however, no compound is currently available with clinically acceptable effectiveness and
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safety. In this study, we investigated the effects of a novel mitochondrial transition pore inhibitor,
N-methyl-4-isoleucine cyclosporin (NIM811), in AP. Pancreatic ductal and acinar cells were
isolatedby enzymatic digestion fromBl/6mice. In vitromeasurementswereperformedby confocal
microscopy andmicrofluorometry. Preventative effects of pharmacological [cylosporin A (2 µM),
NIM811 (2 µM)] or genetic (Ppif−/−/Cyp D KO) inhibition of the mitochondrial transition pore
(mPTP) during the administration of either bile acids (BA) or ethanol + fatty acids (EtOH+FA)
were examined. Toxicity ofmPTP inhibition was investigated by detecting apoptosis and necrosis.
In vivo effects of the most promising compound, NIM811 (5 or 10 mg kg−1 per os), were checked
in three differentAPmodels inducedby either caerulein (10× 50µg kg−1), EtOH+FA (1.75 g kg−1
ethanol and 750 mg kg−1 palmitic acid) or 4% taurocholic acid (2 ml kg−1). Both genetic and
pharmacological inhibition of CypD significantly prevented the toxic effects of BA and EtOH+FA
by restoring mitochondrial membrane potential (ψ) and preventing the loss of mitochondrial
mass. In vivo experiments revealed that per os administration of NIM811 has a protective effect
in AP by reducing oedema, necrosis, leukocyte infiltration and serum amylase level in APmodels.
Administration ofNIM811hadno toxic effects. The novelmitochondrial transition pore inhibitor
NIM811 thus seems to be an exceptionally good candidate compound for clinical trials in AP.
(Received 21 June 2019; accepted after revision 11 October 2019; first published online 21 October 2019)
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Introduction
Acute pancreatitis (AP) is among the most common
gastrointestinal disorders requiring hospitalization in the
United States (Fagenholz et al. 2007a; Peery et al. 2012).
Although the disease is generally mild, the mortality rate
in its severe form is still unacceptably high (Parniczky
et al. 2016). In recent years, our understanding of the
mechanisms that play a crucial role in the development
of the disease has improved (Abu-El-Haija et al. 2018).
Impaired autophagy, trypsinogen activation, excessive
Ca2+ influx, calcineurin activation, mitochondrial
dysfunction and inhibition of the cystic fibrosis trans-
membrane conductance regulator (CFTR) were shown
to have considerable impact in the early phase of AP.
Therefore, targeting one of these mechanisms may lead
to the first specific therapy in AP.
Among the mechanisms noted above, one of the
earliest events in AP is mitochondrial dysfunction (Sah
& Saluja, 2011; Maleth et al. 2013; Abu-El-Haija et al.
2018; Biczo et al. 2018). It has been shown in acinar
cells that bile acids (BAs) and ethanol and fatty acids
(EtOH+FA) open the membrane transition pore (mPTP)
channel via cyclophilin D (Cyp D) activation, keeping
the channel continuously opened and thus resulting in
mitochondrial depolarization, lower ATP synthesis and
cell necrosis (Shalbueva et al. 2013; Mukherjee et al. 2016;
Abu-El-Haija et al. 2018). Although it remains unknown
how the pancreatitis-inducing factors noted abovemodify
mPTP channel activity in pancreatic ductal epithelial cells
(PDECs), it still seems to be one of the most promising
drug targets and calls for further investigation.
Until now, cyclosporin A (CYA) is the only licensed
compound used experimentally to inhibit mPTP (via Cyp
D) (Javed et al. 2018); however, its clinical usefulness is
highlyquestionable for several reasons.Apilot study found
that CYA could reduce the size and damage of myocardial
infarction, but larger studies showed no beneficial effects
(Piot et al. 2008; Cung et al. 2015; Javed et al. 2018). Even
efforts to decrease its immunosuppressive activity havenot
been successful. Moreover, the CYA derivative Debio025
(Alispovirir, Debiopharm, Lausanne, Switzerland) has
been found to be effective against the hepatitis C virus
(HCV), but it had serious side-effects. Surprisingly, some
of thepatientsdevelopedpancreatitis, resulting in a clinical
hold on the global Debio025 trial programme (Zeuzem
et al. 2015; Stanciu et al. 2019). Another derivative,
TRO40303 (3,5-seco-4-nor-cholestan-5-one oxime-3-o,
TROPHOS, Roche, Indianapolis, IN, USA), was not
beneficial in a phase 2 trial of cardiac preservation
following acutemyocardial infarction, suggesting that this
compound has low or no effectivity (Atar et al. 2015).
Indeed it has recently been shown that TRO40303 does
not even bind to Cyp D directly (Sileikyte & Forte, 2016;
Javed et al. 2018). With regard to AP, both Debio025 and
TRO40303 have been shown to be beneficial in animal
models, but neither of themhas reached ‘proof of concept’
clinical trials in AP, probably due to the clinical failures
noted above. New compounds are therefore crucially
needed.
A novel CYA derivative, N-methyl-4-isoleucine cyclo-
sporin (NIM811), was found to be highly beneficial in
different experimental and clinical studies. NIM811 was
effective in animal models of CNS injury (Readnower
et al. 2011), allergic encephalomyelitis (Huang et al. 2017),
ischaemic-reperfusion injury after surgical intervention
(Garbaisz et al. 2014), hepatitis C (Arai et al. 2014),
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Table 1. Solutions used in the present study
Hepes
(Standard)
(mM)
HCO3–
(Standard)
(mM)
NH4Cl−
HCO3–
(mM)
1× TBS
(mM)
HBSS
(Standard)
(mM)
NaCl 140 115 95 150 0.137
KCl 5 5 5 – 5.4
CaCl2 1 1 1 – 0.3
MgCl2 1 1 1 – –
Glucose 10 10 10 – 6
Hepes 10 – – – –
NaHCO3– – 25 25 – 4.2
NH4Cl− – – 20 – –
Trisma base – – – 50 –
Na2HPO4 – – – – 0.25
KH2PO4 – – – – 0.44
MgSO4 - - - - 1.03
liver transplantation (Rehman et al. 2011) and pulmonary
injury during liver transplantation (Liu et al. 2012).
Importantly, none of the studies reported side-effects.
NIM811 had no severe or serious adverse effects in a phase
2 clinical trial on HCV-infected patients, suggesting that
it has no toxic immunosuppressant activity either (Lawitz
et al. 2011).
In this study, we show in several in vitro and in
vivo experiments that either pharmacological or genetic
inhibition of Cyp D restores mitochondrial function not
only in acinar cells, but also in ductal cells, highlighting
the general importance of mPTP in AP. Moreover, we
provide evidence that NIM811 is highly effective in
different experimental pancreatitis models and that it has
no side-effects.
Materials and methods
Ethical approval
The animal experiments were performed in compliance
with European Union Directive 2010/63/EU and
Hungarian Government Decree 40/2013 (II.14.).
Experiments were approved by local ethics committees
for investigations involving animals at the University of
Szeged (XII/4988/2015). In our study all animals were
killed via 200 mg kg−1 pentobarbital I.P. (Bimeda MTC,
Cambridge, Canada).
Animals
Seventy wild type (WT) and Cyp D knockout (Cyp D
KO, (B6;129-Ppiftm1Maf/J) mice were used. Cyp D KO
mice were generated by targeted disruption of the Ppif
gene (which encodes the Cyp D that is a component of
the mPTP) (Baines et al. 2005). Cyp D KO animals were
provided for by the Department of Medical Biochemistry,
Semmelweis University, Budapest, Hungary. WT and Cyp
D-deficient littermate mice (of C57Bl/6J background,
either sex, aged between 20 and 45 days) were housed
in a room maintained at 20–22°C on a 12 h light–dark
cycle with food and water available ad libitum. To ensure a
homologous genetic background, mice were backcrossed
with C57Bl6/J mice for at least eight generations.
Solutions and chemicals
Chemicals were obtained from Sigma-Aldrich (Budapest,
Hungary), unless otherwise stated: 2.7-bis-(2-
carboxyethyl)-5-(and-6-) carboxyfluorescein-acetoxyme-
thylester (BCECF-AM) and tetramethylrhodamine-
methylester (TMRM)were purchased fromThermoFisher
Scientific (Waltham, MA, USA); NIM811 was purchased
from MedChem Express Europe (Sollentuna, Sweden).
CYA, caerulein (CER), NIM811, carbonyl cyanide
3-chlorophenylhydrazone (CCCP) and fluorescence dies
were diluted in DMSO. Table 1 describes the constitution
of solutions that we used during the study. In this
study 500 µM chenodeoxycholic acid (BA) or 100 mM
ethanol (EtOH) + 200 µM palmitoleic acid (FA) were
used during the fluorescence, confocal microscopy and
immunostaining measurements, to evaluate the effect of
bile acids or the alcohol and fatty acid induced damage
on the mitochondrial and cell function during the genetic
or pharmacological inhibition of the mPTP in pancreatic
ducts or acinar cells. CCCP at 100 µM was used in the
mitochondrional measurements as a positive control for
mitochondrial damage.
CYA (2 µM) and NIM811 (2 µM) were used to
pharmacologically inhibit mPTP. Prior to the fluorescence
and confocal microscopy, and immunostaining, the cells
(duct and acinar cells as well) from the CYA- or
NIM811-treated groups were pretreated for 25–30 min
with the compounds (CYA or NIM811).
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Figure 1. Genetic inhibition of Cyp D reduces the severity of bile acid- or ethanol and fatty acid-induced
damage in PDECs
A, mitochondrial membrane potencial measurements revealed that genetic inhibition of mPTP significantly reduces
themitochondrial membrane potencial loss compared toWT controls during the administration of bile acid (500 µM
CDC) or ethanol (100 mM) and fatty acid (200 µM FA) treatment (WT control vs. WT BA ∗∗∗P < 0.001, WT BA vs.
Cyp D KO BA ∗∗P < 0.002, WT control vs. Cyp D KO BA p = 0.712, WT control vs. WT EtOH + FA P < 0.01, WT
EtOH + FA vs. KO EtOH + FA ∗P < 0.05, WT control vs. Cyp D KO EtOH + FA p = 0.145); n = 4–6 experiments
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Table 2. Oligonucleotide primers used in genotyping
Primer Sequence
F-null2 TTCTCACCAGTGCATAGGGCTCTG
LoxP1f AAACTTCTCAGTCAGCTGTTGCCTCTG
CyPuP2 GCTTTGTTATCCCAGCTGGCG
Methods
Genotypes of Cyp D deficient mice were identified by
PCR (typical PCR, analyses from tail genomic DNA). The
PCR-mix contained: TaqDNApol 5U and 10×TaqBuffer
(Abgene, Portsmouth, NH, USA), MgCl2 1.5 mM, dNTP
2.5 mM, F-null2/LoxP1f /CyPuP2 primers (20–20 µM),
dH2O and template DNA sample. The total reaction mix
volume was 25 µl. The wild type allele was detected using
LoxP1f, 5′-AAACTTCTCAGTCAGCTGTTGCCTCTG-3′,
as a forward primer and F-null2, 5′-GCTTTGTTATC
CCAGCTGGCGC-3′, as a reverse primer. For genotyping
of the mutant Cyp D deficient allele, F-null2,
5′-TTCTCACCAGTGCATAGGGCTCTG-3′ was used as a
forward primer with the reverse primer for WT (Table 2).
DNA was denatured at 95°C for 2 min, followed by 30
cycles of amplification: 94°C for 30 s, 60°C for 30 s, 72°C
for 45 s and a final primer extension step at 72°C for 7min.
Bands of 270 and 470 bp were amplified for WT and Cyp
D KO mice, respectively.
Pancreatic ducts and acinar cells were isolated bymicro-
dissection andenzymatic digestion asdescribedpreviously
(Argent et al. 1986; Gout et al. 2013).
The mitochondrial membrane potential () was
determined by using a Zeiss LSM 880 confocal laser
scanning microscope (Carl Zeiss Technika Kft, Budao¨rs,
Hungary). BA or EtOH + FA were used to induce
mitochondrial damage. Isolated pancreatic ducts or acinar
cellswere incubated in standardHepes solutionand loaded
with TMRM (100 nmol l−1).
To monitor apoptotic and necrotic cells in isolated
pancreatic ducts or acinar cells an apoptosis/necrosis kit
was used (ab176750, Abcam, Cambridge, MA, USA). To
determinate live, necrotic or apoptotic cells, CytoCalcein
Violet 450 fluorescent, Apopxin Deep Red Indicator
and Nuclear Green DCS1 fluorescence dies (ab176750,
Abcam) were used. Samples were incubated in the
mixture of the above stated fluorescence dyes at room
temperature for 30–35 min (after 25 min of treatment
with BA/EtOH + FA/CYA/NIM811) in the dark prior
to the confocal microscopy measurements. For CYA- or
NIM811-treated ducts or acinar cells, incubation with
these compounds were performed before staining with
the fluorescence dyes. Stainings were analysed using a
Zeiss LSM 880 confocal laser scanning microscope. Live,
necrotic or apoptotic cells were counted and summarized
as a percentage of each sample, and data were then
averaged and statistical analysis was performed.
Microfluorometry was used to measure pancreatic
ductal HCO3− secretion as described earlier (Hegyi
et al. 2013; Hegyi et al. 2004) by using BCECF-AM
(1.5 mmol l−1).
Functionally active mitochondria were detected with
immunofluorescent staining (TOM20 mitochondrial
marker EPR15581-39, Abcam). To determine
mitochondrial localization in isolated pancreatic
ductal or acinar cells we labelled the mitochondria by the
using TOM20 primary antibody (Abcam, EPR15581-39).
TOM20 is the central unit of the receptor TOM complex
in the mitochondrial outer membrane and its role is
to recognize and translocate cytosolically synthetized
mitochondrial preproteins (Schatz et al. 1996; Pfanner,
1998; Rapaport, 2002). Isolated pancreatic ducts were
frozen in cryomold at 20°C. The cryosections (thickness
7 µm) of the isolated pancreatic ducts from WT and Cyp
D KO mice were cut via a Leica Cryostat. Sections were
fixed in 4% paraformaldehyde. Washing periods were
administered with 1×Tris-buffered saline (TBS) solution.
Antigen retrieval was performed with 10 mM sodium
citrate solution at pH 6 at 95°C for 15 min. Blocking
was obtained for 1 h with 1% goat serum in 5% bovine
serum albumin (BSA)-TBS solution. These sections were
then incubated with TOM20 rabbit monoclonal antibody
(dilution 1:400, Abcam) overnight at 4°C. The following
day the samples were incubated with goat anti-rabbit
secondary antibody (Alexa fluor 488, Thermo Fisher)
for 2 h in the dark in room temperature. Nuclei were
counterstained with Hoechst 33342 (Thermo Fisher).
Immunofluorescence staining of the isolated pancreatic
acinar cells was performed immediately after the isolation
procedure with the same conditions as stated above
(except: cells were fixed in 2% paraformaldehyde and
dilution of the primary antibody was 1:200). Both ductal
per group; data are means ± SEM. B, immunostaining revealed a significant decrease of the TOM20 stainings in
BA-, EtOH + FA- or CCCP-treated WT ducts; results were compared to Cyp D KO stainings (∗P < 0.05). C, genetic
inhibition of mPTP also decreased the necrosis and apoptosis levels during bile acid; ethanol and fatty acid or CCCP
treatment (∗P< 0.05) D, representative traces from the pancreatic ductal HCO3– secretion measurements. E and F,
the data revealed that levels of alkalosis recovery were significantly lower due to BA or EtOH + FA administration
(∗P < 0.05) compared to the results from Cyp D KO ducts. Levels of alkalosis recovery were significantly lower
in the WT ducts due to the treatment with BA or EtOH + FA (∗P < 0.05), while in Cyp D KO ducts these levels
were significantly higher (∗P < 0.05). n = 5–7 experiments per group; data are means ± SEM. y axis=base
flux [–J(B–/min)] was calculated from the 1pH/1t obtained by linear regression analysis of pHi (HCO3-secretion)
measurements. [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 2. CYA reduces the severity of bile acid- or ethanol and fatty acid-induced pancreatic ductal
damage
A, treatment with 2 µM CYA reduced the drop of mitochondrial membrane potencial loss which accured due to
the BA or EtOH + FA treatment (WT vs. CYA). In WT ducts BA or EtOH + FA treatment resulted in significantly
reduced mitochondrial membrane potencial (WT control vs. WT BA ∗P < 0.05, WT control vs. WT EtOH + FA
P < 0.05), while between WT control groups compared to CYA-treated BA or EtOH + FA there was no significant
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and acinar cell samples were mounted with Fluoromount
and then analysed using a Zeiss LSM 880 confocal laser
scanning microscope. To quantify TOM20 positively
stained area, five or six representative images from each
group were taken by with the Zeiss LSM 880 microscope.
Image J software was used to convert images to grey
scale (16 bit), and threshold function was used to select
the positively stained area. The fluorescence signal
was calculated by the software [arbitrary scale from
0-negative (white) to 255-maximal staining (black)]
(Venglovecz et al. 2018). Fluorescence intensity of the
images was then normalized to the total ductal or acinar
area of the samples, which were measured in arbitrary
units. Fluorescence intensity was given as a percentage,
normalized to the total ductal or acinar total area.
AP was induced by CER (10× 50 µg kg−1), 4% sodium
taurocholate (TAU, 2 ml kg−1, 4%) (Niederau et al. 1985;
Ding et al. 2003; Perides et al. 2010; Pallagi & Balla et al.
2014) or alcohol and fatty acid (I.P. injection of 1.75 g kg−1
ethanol and 750 mg kg−1 palmitic acid, EtOH + FA) as
described previously (Huang, 2014;Maleth et al. 2016). All
control groups received physiological saline in the same
amount as the CER, EtOH + FA or the TAU solutions
respectively. Pre-treatment of the animals by NIM811 was
performed and mice were gavaged orally once 1 h prior to
the induction of AP (concentrations of NIM811 were 10
or 5 mg kg−1). The dose of NIM811 was chosen according
to a previous study in which NIM811 was effective against
mitochondrial damage in liver transplantation (Rehman
et al. 2011). Oral gavage treatment were performed by the
use of plastic feeding tubes (20 gauge × 38 mm, Instech
Laboratories, PlymouthMeeting, PA,USA).NIM811were
solubilized in a vehicle which contained 8.3% polyoxyl 40
hydrogenated castor oil and 8.3% ethanol (Rehman et al.
2011).
NIM811 was used as a post-AP treatment as well.
NIM811 was administered 12 h after the induction of
AP in the TAU- or EtOH + FA-induced experimental
pancreatitis models. Concerning the CER-induced AP,
NIM811 was administered after the third injection
of CER. The method for retrograde intraductal
infusion of TAU has been described by Perides et al.
(2010). The surgery was performed on anaesthetized
mice (with ketamine–xylazine, dosage: 87.5 mg kg−1
ketamine/12.5 mg kg−1 xylazine). At the end of the
procedure the mice were placed on a heating pad for
40 min and received buprenorphine I.P. (0.075 mg kg−1)
immediately to reduce pain. Following these mice were
replaced into their cages for 24 h. They had free access
to food and water. Twenty-four hours after the TAU-
or EtOH + FA-induced AP the mice were killed via I.P.
200 mg kg−1 pentobarbital (Bimeda MTC, Cambridge,
Canada). During the CER-induced AP mice were killed
with I.P. 200 mg kg−1 pentobarbital (Bimeda MTC) 2 h
after the last injections of CER. Mice were exsanguinated
through cardiac puncture and the pancreas was removed.
Blood from the cardiac puncture was placed on ice,
then centrifuged with at 2500 g for 15 min at 4°C.
Blood serum was collected from the pellet and stored
at −20°C until use. Pancreas samples were placed into
8% neutral formaldehyde solution and stored at −4°C
until the haematoxylin–eosin staining was performed.
A colorimetric kit was used to measure serum amylase
activity (Diagnosticum, Budapest, Hungary). Absorbance
of the samples was detected at 405 nm with the use of a
FLUOstar OPTIMA (BMG Labtech, Budapest, Hungary)
microplate reader. Formaldehyde-fixed pancreas samples
were embedded in paraffin and were cut into 3 µm
thick sections and stained for haematoxylin–eosin by
using a standard laboratory method. To quantify
oedema, necrosis and leukocyte infiltration grades a
semiquantitative scoring system was used according to
Kui et al. (2015).
In vitro pancreatic ductal fluid secretion (luminal
swelling) assayswere developedbyFerna´ndez-Salazar et al.
(2004) performed by videomicroscopy as described by
Bala´zs et al. (2018). Briefly, stimulation of pancreatic
ductal fluid secretion was induced by 5 µM forskolin
and 100 µM 3-isobutyl-1-methylxanthine (IBMX), and
quantification were performed using ImageJ software
(Bala´zs et al. 2018). In vivo fluid secretion measurements
were performed on anaesthetized (I.P. 87.5 mg kg−1
ketamine/12.5 mg kg−1 xylazine) mice after CER- or
EtOH + FA-induced AP before the animals were killed.
Animals were placed on warm pads (37°C) to maintain
body temperature. Briefly, the abdomen was opened and
decrease. B, TOM20 levels were significantly reduced in BA, EtOH + FA or CCCP control (not CYA treated) ducts,
while in the CYA-treated groups the percentage of TOM20-stained area was significantly higher (∗P < 0.05).
Between the control groups (WT control or only CYA-treated samples) we found no significant alterations in the
stainings. C, necrosis was much higher in BA- or EtOH-treated groups in WT ducts but not in CYA-treated groups.
Apoptosis levels were significantly higher as well in the non-CYA-treated groups compared to the CYA-treated
groups. Measurements of HCO3− secretion levels revealed a significant difference in WT and CYA-treated ducts
during administration of BA (P< 0.05 WT BA vs. CYA BA) or EtOH + FA (∗P< 0.05). E and F, in WT ducts the levels
of base flux [-J(B-/min)] grades were significantly decreased due to BA (WT vs. WT BA P < 0.05) or EtOH + FA
(WT vs. WT EtOH + FA P < 0.05) treatment. Recovery from alkalosis (E) and recovery from acidosis (F) values are
presented ± SEM. Comparison within CYA-treated groups revealed no significant difference (CYA control vs. CYA
BA p = 0.644). y axis=base flux [–J(B–/min)] was calculated from the 1pH/1t obtained by linear regression analysis
of pHi (HCO3-secretion) measurements. [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 3. NIM811 protects mitochondrial and cell function in PDECs
A, NIM811-treated ducts revealed a significantly consolidated loss of mitochondrial membrane potential during
the BA (WT BA vs. NIM811 BA ∗P < 0.05) or EtOH + FA (WT EtOH + FA vs. NIM811 EtOH + FA ∗P < 0.05)
treatment. In NIM811-treated ducts the percentage of fluorescence intensity was significantly higher compared
to non-NIM811-treated ducts during BA or EtOH + FA administration. B, in CCCP-treated ducts we found no
significant difference in the amount of TOM20 staining in NIM811-treated or untreated groups. NIM811 itself did
not alter the level of TOM20 staining compared to the WT control samples. C, NIM811 decreased the numbers of
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apoptotic and necrotic cells during bile acid or ethanol and fatty acid treatment (WT BA vs. NIM811 BA ∗P < 0.05,
WT EtOH + FA vs. NIM811 ∗P < 0.05). During the administration of CCCP the apoptosis and necrosis grades
were not significantly different in the comparative groups. D–F, NIM811 treatment did not decrease the HCO3−
secretion grade (control), while during the administration of BA or EtOH + FA it had a protective effect against
the reduction of HCO3− secretory levels (E, F) (WT BA vs. NIM811 BA ∗P < 0.05, WT EtOH + FA vs. NIM811
EtOH + FA ∗P < 0.05). Regarding recovery levels from alkali load during EtOH and FA treatment, differences were
not significant in WT EtOH + FA- compared to the NIM811 and EtOH + FA-treated groups (E). [Colour figure can
be viewed at wileyonlinelibrary.com]
cannulation of the lumen of the common biliopancreatic
duct was performed with a 30-gauge needle (Male´th
et al. 2016). The proximal end of the common duct was
closed by a microvessel clip (Braun-Aesculap, Tuttlingen,
Germany) to prevent contamination with bile, and the
pancreatic juice was collected in a PE-10 tube for 15 min.
In vivo secretion was induced by I.P. administration of
0.75 CU kg−1 secretin (Male´th et al. 2016).
Statistical analysis
All data are expressed as means ± SEM. Data were
compared by either one- or two-way ANOVA or
Figure 4. Pancreatic ductal fluid secretion is not altered by NIM811 or CYA treatment
A, in vitro fluid secretion was stimulated by 5 µM forskolin and 100 µM IBMX (stimulation). B and C, BA or EtOH+ PA
treatment inhibited luminal swelling. D, relative luminal volume changes during forskolin and IBMX stimulation.
Means ± SEM; n = 5–10 ducts per group. E and F, in vivo fluid secretion measurements were performed after
CER- or EtOH + FA-induced AP. These experiments confirmed that pancreatic ductal fluid secretion is not affected
by NIM811 or CYA. ∗P < 0.05 WT PS vs. WT EtOH + FA, P < 0.05 WT PS vs. WT CER n = 4–7 animals per group.
[Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 5. NIM811 treatment protects mitochondrial function in pancreatic acinar cells
A, mitochondrial membrane potential measurements revealed a significant difference between WT untreated and
NIM811-treated acinar cell response due to bile acid or ethanol and fatty acid treatment (WT BA vs. NIM811 BA
∗P < 0.05; WT EtOH + FA vs. NIM811 EtOH + FA ∗ P < 0.05). A significant difference was detected between
the NIM811-treated acinar cells and the groups which were not treated with NIM811 during BA or EtOH + FA
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Kruskal–Wallis tests followed by the Holm–Sidak method
as appropriate (Sigma Plot). The effects were considered
significant at p < 0.05.
Results
Genetic inhibition of mPTP protects mitochondrial
homeostasis and cell function evoked by
pancreatitis-inducing factors in PDECs
First, we measured the effects of the most relevant
pancreatitis-inducing factors onmitochondria in primary
intact ducts isolated from Ppif−/− and WT mice.
Experiments with TMRM and TOM20 revealed that
genetic inhibition of mPTP decreased both the loss
of ψ (Fig. 1A) and mitochondrial mass (Fig. 1B)
caused by 500 µM chenodeoxycholic acid (CDC; BA)
or co-administration of 100 mM ethanol and 200 µM
palmitoleic acid (EtOH+ FA). Co-staining the pancreatic
ducts with CytoCalcein Violet, Apopxin Deep Red and
Nuclear Green showed that genetic inhibition of mPTP
also decreased the extent of necrosis and apoptosis during
the administration of BA or EtOH + FA (Fig. 1C),
suggesting that genetic inhibition ofCypDhas a protective
effect on PDECs. Next, we investigated how the genetically
preserved mitochondrial function affects the cellular
function of PDECs (Fig. 1D). We used the NH4Cl pulse
technique, which is uniquely suited to characterizing both
HCO3− influx and efflux mechanisms. Our experiments
demonstrated that the inhibitory effects of BA and
EtOH + FA on Cl−/HCO3− exchangers (HCO3− efflux)
andonNa+/HCO3− co-transporters (HCO3− influx)were
totally blocked in Ppif−/− vs. WT mice, suggesting that
inhibition of mPTP can preserve ductal function and thus
has therapeutic benefits (Fig. 1D–F).
Pharmacological inhibition of mPTP by CYA
effectively prevents mitochondrial damage evoked
by pancreatitis-inducing factors in PDECs
Both BA and EtOH + FA significantly decreased
the ψ of PDECs (Fig. 2A). Importantly, 2 µM CYA
effectively blocked the toxic effects of the BA- and
EtOH + FA-preserving function of mitochondria during
the presence of pancreatitis-inducing factors. As regards
the quantity of mitochondria, CYA effectively inhibited
loss, as observed during the genetic inhibition of mPTP
(Fig. 2B). CYA at 2 µMdecreased the extent of necrosis and
apoptosis during the administration of BA or EtOH + FA
in PDECs (Fig. 2C). Finally, we provided strong evidence
of the beneficial effects of CYA on mPTP noted above,
mitochondrial mass and cell death, resulting in preserved
HCO3− efflux and influx mechanisms during BA or
EtOH + FA administration (Fig. 2D–F).
NIM811 treatment protects mitochondrial function
and preserves bicarbonate transport mechanisms in
PDECs
Next, we investigated the effects of the novel CYA
derivative NIM811 on mitochondrial function and of
bicarbonate secretion on isolated pancreatic ducts.
According to our data, NIM811 reduces the BA- or
EtOH + FA-induced damage to mitochondrial function
and morphology in isolated pancreatic ducts (Fig. 3A,
B). Experiments using CytoCalcein Violet, Apopxin Deep
Red andNuclear Green showed that NIM811 alone has no
toxic effects on PDECs. Furthermore, it strongly decreases
BA- or EtOH-FA-evoked necrosis and apoptosis (Fig. 3C).
NH4Cl− experiments revealed that the inhibitory effects of
BA and EtOH + FA on Cl−/HCO3− exchangers (HCO3−
efflux) and on Na+/HCO3− co-transporters (HCO3−
influx) were significantly reduced in the NIM811-treated
groups compared to the controls, showing a protective
effect of NIM811 on PDECs (Fig. 3D).
NIM811 and CYA have no effects on pancreatic ductal
fluid secretion
Both in vivo and in vitro measurements revealed that
NIM811 or CYA treatment did not prevent BA- or
EtOH + FA-induced fluid secretiory damage in isolated
ducts (Fig. 4A–D and E, F).
NIM811 treatment protects mitochondrial function in
acinar cells
In vitromeasurements of freshly isolated pancreatic acinar
cells showed that NIM811 treatment decreased the BA-
and EtOH-FA-induced loss of ψas effectively as seen
in PDECs (Fig. 3A). However, results obtained from
TOM20 staining suggest that NIM811 has no effect on
mitochondrial mass in acinar cells (Fig. 5B). Micro-
fluorometric measurements demonstrated that NIM811
alone has no toxic effects on acinar cells and has no effect
on BA- or EtOH-FA-induced apoptosis, but is protective
against BA- or EtOH-FA-induced necrosis (Fig. 5C).
treatment. B, mitochondrial protein TOM20 levels did not show a difference in the NIM811-treated or untreated
groups after BA, EtOH + FA or CCCP treatment (P > 0.05). C, a significant difference in necrosis levels was
found between NIM811-treated and untreated groups in BA or EtOH + FA (∗P < 0.05). However, no difference
was found for the CCCP-treated groups. Apoptosis levels were not altered significantly by NIM811 during BA or
EtOH + FA treatment. [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 6. NIM811 reduces the severity of CER induced AP
A, representative images of pancreas sections. B, serum amylase levels were elevated in the CER-treated groups
and NIM811 treatment resulted in a reduced serum amylase levels during CER-induced AP compared to the WT
CER group (∗∗∗P < 0.01 WT PS vs. WT CER, ∗∗P < 0.02 WT CER vs. pre 10 mg kg−1 NIM811 CER, ∗P < 0.05
WT CER vs. pre 5 mg kg−1 NIM811 CER, p = 0.717 CER + pre 5 mg kg−1 NIM811 vs. CER + pre 10 mg kg−1
NIM811). A–E, for CER-induced pancreatitis both 5 mg kg−1 body weight NIM811 (P < 0.05 WT CER vs. pre
5 mg kg−1 NIM811 CER) and pre 10 mg kg−1 NIM811 (P < 0.05 WT CER vs. pre 10 mg kg−1 NIM811 CER)
treatment reduced the CER-induced damage. F–K, post 5 mg kg−1 NIM811 treatment significantly reduced serum
amylase levels compared to WT CER ( P < 0.05, P < 0.001 WT PS vs. WT CER. H, post-insult administration of
10 mg kg−1 NIM811 significantly reduced oedema and leukocyte infiltration levels compared to WT CER-treated
groups ( P < 0.05, n = 8–10 animals per group, data are means ± SEM). [Colour figure can be viewed at
wileyonlinelibrary.com]
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Figure 7. NIM811 reduces the severity of TAU induced AP in mice
A–K, in TAU-induced pancreatitis, serum amylase measurements revealed that retrogrode infusion of TAU led to
elevated serum amylase levels [∗∗∗P < 0.01 WT PS vs. WT TAU (B), P < 0.001 WT PS vs. WT TAU (G)], but
5 or 10 mg kg−1 body weight NIM811 treatment significantly reduced the enzyme levels both before and after
treatment (B: ∗∗P < 0.02 WT TAU vs. pre 5 mg kg−1 NIM811 + TAU, ∗∗P < 0.02 WT TAU vs. pre 10 mg kg−1
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NIM811 + TAU, P < 0.001 WT TAU vs. post 5 mg kg−1 NIM811 TAU, P < 0.001 WT TAU vs. post
10 mg kg−1 NIM811 + TAU), and serum amylase levels were reduced compared to WT TAU-treated groups
(B and G: ∗P < 0.01 WT TAU vs. WT 5 mg kg−1 NIM811 TAU and ∗P < 0.01 WT TAU vs. WT 10 mg kg−1
NIM811 TAU). During pre-NIM811 treatment oedema, necrosis and leukocyte infiltration scores were significantly
decreased compared to the only TAU-treated groups (A, C, D, E: P < 0.05 WT TAU vs. pre 5 mg kg−1 NIM811
TAU/10 mg kg−1 NIM811 TAU). Post-insult administration of NIM811 decreased oedema, leukocyte infiltration
and necrosis levels in the TAU group (G–K: P < 0.001). n = 4–6 animals per group; data are means ± SEM.
[Colour figure can be viewed at wileyonlinelibrary.com]
NIM811 has therapeutic benefits in CER-, TAU- and
EtOH-FA-induced AP
First, we confirmed that per os administration of either 5
or 10 mg kg−1 NIM811 alone has no toxic effect on the
pancreas (Fig. 9). Second,we tested the compound in three
different experimental APmodels: the CER-, EtOH+ FA-
and TAU-induced models (Niederau et al. 1985;
Perides et al. 2010; Huang, 2014). Importantly, pre-
treatment with both 5 and 10 mg kg−1 NIM811
significantly reduced the elevation of serum amlylase
activity, as well as pancreatic oedema, necrosis and
leukoctye infiltration in experimental AP models
(Figs 6–8). We also confirmed that subsequent treatment
with 5 or 10mgkg−1 NIM811 has protective effects against
pancreatic damage (Figs 6–8).
Discussion
AP is a multifactorial disease (Hegyi & Petersen, 2003;
Sahin-Toth & Hegyi, 2017) involving several types of cell,
including acinar and ductal cells. None of the therapeutic
efforts targeting only one of them has been successful.
Intravenous administration of secretin, which targeted
ductal cells only, was found to be either slightly beneficial
or neutral in AP (Lankisch et al. 1983; Renner et al. 1983;
Keim et al. 1985). By contrast, neither gabexate mesilate
nor trasylol, which effectively inhibit trypsin activity,
had beneficial effects in AP (Imrie et al. 1978; Buchler
et al. 1993). Therefore, we need to find common targets
which can restore both acinar and ductal cell functions
in AP.
Mitochondrial damage is one of the key
pathophysiological events in the early phase of AP
in both types of cell (Hegyi & Petersen, 2003; Maleth
et al. 2013; Maleth & Hegyi, 2015). It decreases ATP
production, causing an elevation of intracellular
calcium concentration; moreover, it negatively influences
ATP-dependent Cl−/HCO3− exchangers, CFTR Cl−
channels in ductal cells and enzyme secretory processes
in acinar cells (Maleth et al. 2011, 2013, 2015; Judak
et al. 2014; Maleth & Hegyi, 2015; Mukherjee et al.
2016; Biczo et al. 2018; Katona et al. 2016). In addition,
mitochondrial damage is the main factor in determining
cell death pathway necrosis and apoptosis. Release of
mitochondrial cytochrome c into the cytosol causes
apoptosis, whereas mitochondrial depolarization leads
to necrosis (Odinokova et al. 2008). Generally, the
standard apoptotic pathway involves mitochondrial outer
membrane permeabilization, which causes apoptotic
factors such as cytochrome c to be released from the inner
membrane to the cytosol (Tait & Green, 2010; Maleth
& Hegyi, 2015). On the other hand, opening of the
mPTP leads to loss of ψ, ATP depletion, increased inner
membrane permeability, mitochondrial swelling and
necrotic cell death (Golstein & Kroemer, 2007; Halestrap
et al. 2009; Maleth & Hegyi, 2015). Uniquely, inhibition
of mPTP could prevent both cell death mechanisms
in PDECs, which is different from that seen in acinar
cells, where only necrosis could have been prevented.
Inhibition of mPTP thus seems to be highly beneficial
in both cell types. In the last decade, it has been shown
that genetic or pharmacological inhibition of mPTP
reduces BA- or EtOH + FA-induced acinar cell damage
as well as augmenting the severity of AP (Sah & Saluja,
2011; Gukovskaya et al. 2016; Mukherjee et al. 2016;
Biczo et al. 2018). As regards ductal cells, we have shown
earlier that both BA and EtOH + FA induce inhibition
of HCO3− secretion via severe mitochondrial damage
in PDECs (Maleth et al. 2011, 2016). Now, we have
continued our experiments investigating the role of
mPTP and its inhibition in this type of epithelial cell.
First, we characterized the role of mPTP (both genetic and
pharmacological CYA) inhibition in PDECs and found
that its inhibition has a strong protective effect against the
toxic effects of BA or EtOH+ FA in ductal cells, suggesting
that targeting mPTP may have general benefits. Although
many mPTP inhibitors have been tested, none of them
has been successful. CYA itself inhibits calcineurin, which
leads to immunosuppressant activity and thus could
negatively affect the treatmentof patients due tohazardous
infections. Clinical testing of non-immunosuppressive
CYA derivatives Debio025 and TRO40303 was also
stopped before reaching ‘proof of concept’ phase 2
clinical trials in AP because of its inconsistent behaviour
in other trials (see Introduction). Recently, other new
mPTP inhibitors have been introduced in experimental
studies. Isoxazoles had inconsistent effects in myocardial
infarction (Sileikyte & Forte, 2016). Benzamides resulted
in impaired ATP generation (Sileikyte & Forte, 2016;
Javed et al. 2018). Cinnamic anilides were shown to be
effective in myocardial infarction (Fancelli et al. 2014);
however, it has since been shown that it has an age-related
toxicity (Fang et al. 2019). In contrast, NIM811 seemed
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Figure 8. NIM811 has a protective effect against EtOH + FA induced pancreatic damage
A–K, in EtOH + FA-induced pancreatitis, serum amylase measurements revealed that in pretreatment with
10 mg kg−1 NIM811 significantly reduced serum amylase levels (B: ∗∗P< 0.002 WT EtOH + FA vs. pre 10 mg kg−1
NIM811 + EtOH + FA; B and G: ∗∗P < 0.002 WT PS vs. WT EtOH + FA), whereas with post-NIM811 treatment
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serum amylase levels did not differ significantly compared to its EtOH + FA control (G). With pre 10 mg kg−1
NIM811 treatment leukocyte infiltration (∗∗∗P < 0.001 WT EtOH + FA vs. 10 mg kg−1 NIM811) and necrosis
levels (∗∗∗P < 0.001 WT EtOH + FA vs. 10 mg kg−1 NIM811) were significantly reduced compared to EtOH + FA
AP group (D–E). C–E: ∗∗∗P < 0.001 WT PS vs. Wt EtOH + FA. Oedema and leukocyte infiltration levels were
significantly reduced in post 5 mg kg−1 NIM811-treated groups compared to WT EtOH + FA groups (H and K:
∗P < 0.05 WT EtOH + FA vs. post 5 mg kg−1 NIM811). n = 4–7 animals per group; data are means ± SEM.
[Colour figure can be viewed at wileyonlinelibrary.com]
Figure 9. NIM811 itself does not induce pancreatic damage
No significant difference was found between the NIM811-treated - (8.3% polyoxyl 40 hydrogenated castor
oil, 8.3% EtOH) vs. the control groups. n = 4–5 animals per group. [Colour figure can be viewed at
wileyonlinelibrary.com]
to be a perfect choice. It has been shown to be protective
in several diseases, and until now no toxic effects have
been demonstrated. Therefore, we continued our study
by testing the effects of NIM811 on both ductal and
acinar cells in vitro. We found that NIM811 reduces the
mitochondrial damage caused by BA or EtOH + FA.
Importantly, NIM811 decreased apoptosis levels during
BA or EtOH + FA treatment in ductal cells, but not in
acinar cells, a result which could be due to the observation
that ductal cells have more mitochondria than acinar cells
(Maleth et al. 2013). Surprisingly, inhibition of mPTP
protected pancreatic ductal bicarbonate but not fluid
secretion during BA or EtOH + FA treatment. These
data suggest that rescuing intracellular ATP levels and
the activity of Na+/K+-ATPase do not result in overall
protection alone and other fluid transport mechanisms
such as aquaporins may remain diminished (Venglovecz
et al. 2018). Per os administration of 5 or 10 mg kg−1
NIM811 alone had no toxic effect, but significantly
reduced the severity of AP. We found that NIM811
treatment was more beneficial in the TAU- than in the
EtOH + FA-induced AP model. One explanation could
be that besides the direct toxic effect of EtOH and FA, the
non-oxidative metabolites of FA (fatty acid ethyl esters)
have even higher toxicity on the mitochondria in both
acinar and ductal cells (Criddle et al. 2006; Petersen et al.
2009).
Taken together, mitochondrial function and
bioenergetics play a crucial role in the development
of AP; however, translation of these results to a patient
benefit remains lacking (Maleth et al. 2013; Gukovskaya
et al. 2016; Maleth & Hegyi, 2015; Mukherjee et al. 2016;
Biczo et al. 2018). In this study, we have confirmed
that the mPTP inhibitor NIM811 is a highly suitable
compound to be tested in clinical trials. As a next step,
phase 2 clinical trials are needed with the use of this novel
and promising drug candidate.
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Translational perspective
Acute pancreatitis (AP) is a severe disorder with high morbidity, mortality and no specific treatment.
It is generally accepted that one of the earliest events in initiation of the disease is mitochondrial
dysfunction and ATP depletion. It has been shown that the pancreatitis-inducing factors ethanol, fatty
acids and bile acids open the membrane transition pore (mPTP) channel, and keep it continuously
open, resulting in mitochondrial depolarization, lower ATP synthesis and cell necrosis both in
pancreatic acinar and ductal cells. In this study, we provided strong evidence that one of the mPTP
inhibitors, namely NIM811, is highly effective in different experimental pancreatitis models. Since
NIM811 had no side-effects and passed the important phase 1 stage in the clinical trial process, phase
2 clinical trials are needed with the use of this novel and promising drug candidate.
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